These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 18247475)

  • 41. Liver-enriched nuclear receptors: therapeutic opportunities.
    Staudinger JL
    Mol Pharm; 2008; 5(1):1-2. PubMed ID: 18247475
    [No Abstract]   [Full Text] [Related]  

  • 42. Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.
    Staudinger JL; Lichti K
    Mol Pharm; 2008; 5(1):17-34. PubMed ID: 18159925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FXR: a metabolic regulator and cell protector.
    Wang YD; Chen WD; Moore DD; Huang W
    Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Signal transduction of steroids and vitamins mediated by nuclear receptor proteins].
    Umesono K
    Tanpakushitsu Kakusan Koso; 1996 Jun; 41(8 Suppl):1265-72. PubMed ID: 8741648
    [No Abstract]   [Full Text] [Related]  

  • 45. Nuclear receptor variants in liver disease.
    Zimmer V; Liebe R; Lammert F
    Dig Dis; 2015; 33(3):415-9. PubMed ID: 26045277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies.
    Lemaigre FP
    Gastroenterology; 2009 Jul; 137(1):62-79. PubMed ID: 19328801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?
    Boyer JL
    Gastroenterology; 2005 Aug; 129(2):735-40. PubMed ID: 16083726
    [No Abstract]   [Full Text] [Related]  

  • 48. Cannabinoid receptors as therapeutic targets in the management of liver diseases.
    Mallat A; Lotersztajn S
    Drug News Perspect; 2008 Sep; 21(7):363-8. PubMed ID: 19259549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigational pharmacologic treatment for liver disease.
    Siatkosky LL; Shermock KM; Younossi ZM
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1281-93. PubMed ID: 12225249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-122, a paradigm for the role of microRNAs in the liver.
    Girard M; Jacquemin E; Munnich A; Lyonnet S; Henrion-Caude A
    J Hepatol; 2008 Apr; 48(4):648-56. PubMed ID: 18291553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toll-like receptors and adaptor molecules in liver disease: update.
    Seki E; Brenner DA
    Hepatology; 2008 Jul; 48(1):322-35. PubMed ID: 18506843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NF-kappaB signaling, liver disease and hepatoprotective agents.
    Sun B; Karin M
    Oncogene; 2008 Oct; 27(48):6228-44. PubMed ID: 18931690
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.